Prodrugs are mainly designed to improve the bioavailability of parent drugs for oral delivery and parenteral administration [1,3,4] by increasing aqueous solubility or membrane permeability, for example, anesthetic fospropofol [11], angiotensin-converting enzyme (ACE) inhibitors enalapril [12], and sofosbuvir for hepatitis C virus infection therapy [13] (Figure 1A). This evidence concerns the gene ACE and hepatitis C virus infection.